Provided By GlobeNewswire
Last update: Sep 3, 2025
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway, with a focus on severe eye diseases, today announced that Company management will present at an upcoming healthcare investor conference.
Read more at globenewswire.comNASDAQ:SRZN (10/10/2025, 8:58:29 PM)
13.7664
+0.02 (+0.12%)
Find more stocks in the Stock Screener